Sporos Bioventures

Tvardi Therapeutics develops oral small molecule therapies targeting STAT3 for treating fibrosis-driven diseases such as idiopathic pulmonary fibrosis (IPF) and hepatocellular carcinoma (HCC).

Founded in Houston, Texas in 2019, Asylia Therapeutics is a biotechnology company dedicated to developing novel immune-modulating therapies for autoimmune diseases, cancer, and infections. Its proprietary platform focuses on modulating antigen presentation to the immune system, demonstrating promising anti-tumor responses across various cancer models.

Nirogy Therapeutics is a biotechnology company focused on developing innovative small molecules that target cellular transporters to address chronic diseases, including cancer, autoimmune disorders, and inflammation. The company employs a transporter target platform that integrates transporter biology, structural biology, and computational chemistry to analyze underlying biological mechanisms. This approach informs drug design and development while also guiding patient selection strategies for new therapies. Nirogy is advancing a specific class of small molecules aimed at disrupting metabolic and immune processes within the tumor microenvironment, with additional programs targeting various disease pathways in oncology and autoimmune diseases, ultimately seeking to meet significant unmet medical needs in healthcare.